Biogen (BIIB) PT Raised to $367 at Leerink Partners

Baird Incrementally Positive on Biogen (BIIB) Nusinersen Data; PT to $284

Baird analyst Brian Skorney bumped his price target on Biogen (NASDAQ: BIIB) to $284.00 (from $268.00) but lefts his Neutral rating, saying they are incrementally positive on nusinersen interim Phase 3 results.

Skorney commented, "Results are in, earlier than expected, and nusinersen appears to... More

Stifel Affirms Biogen at 'Hold' Following Strong Nusinersen Phase 3 Data

Stifel affirms Biogen (Nasdaq: BIIB) at Hold after the company and Ionis Pharmaceuticals announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with... More

Biogen (BIIB) PT Raised to $304 at BMO Capital

BMO Capital analyst M. Ian Somaiya raised his price target on Biogen (NASDAQ: BIIB) to $304.00 (from $286.00) following announcement that nusinersen hit the motor function primary endpoint in an interim analysis from the P3 trial, but maintained a Market Perform rating.

Somaiya... More

Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with Type 1) SMA. The analysis found that infants receiving nusinersen experienced a statistically significant improvement in the achievement of motor milestones compared to those who did not receive treatment. Nusinersen demonstrated an acceptable safety profile in the trial. As a result of these findings, Biogen has exercised its option to develop... More